Tag: Abivax
Abivax: appointments to follow
By Claude Leguilloux Published on 06/10/2023 at 09:19 a.m. Abivax remains stable at 13 euros, while the clinical-stage biotechnology company focused on the development…
Abivax announces new results on its flagship product obefazimod – 02/10/2023 at 6:19 p.m.
(AOF) – Abivax announced today that three datasets on its lead drug candidate, obefazimod, will be presented at the United European Week of Gastroenterology (UEG) meeting, October 14-17, 2023, in…
Abivax highlights its clinical development program for obefazimod in ulcerative colitis
By Claude Leguilloux Published on 02/10/2023 at 6:49 p.m. Photo credit © Abivax (Boursier.com) — Abivax SA, a…
Abivax announces new results on its flagship product obefazimod
(AOF) – Abivax announced today that three datasets on its lead drug candidate, obefazimod, will be presented at the United European Week of Gastroenterology (UEG) meeting, October 14-17, 2023, in…
Abivax: the plan for listing in the United States is moving forward
(AOF) – Abivax (-2.27% to 2.66 euros) announces the filing of a Form F-1 registration document with the US Securities and Exchange Commission (SEC) as part of its project IPO…
Abivax: the listing project in the United States is moving forward – 02/10/2023 at 11:31
(AOF) – Abivax (-2.27% to 2.66 euros) announces the filing of a Form F-1 registration document with the US Securities and Exchange Commission (SEC) as part of its project IPO…
Abivax announces the publication of its 2023 half-year financial report – 09/29/2023 at 6:10 p.m.
PARIS, France, September 29, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of…
Abivax announces the filing of a registration document form F-1 with a view to its planned initial public offering in the United States and the filing of an amendment to its universal registration document – 09/29/2023 at 11:00 p.m.: 10
PARIS, France, September 29, 2023 – 11:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of…
Abivax: challenge met!
(Boursier.com) — Abivax takes 1% to 16.50 euros this Friday, while the biotechnology company presented its 2023 half-year financial results. The operating result is -37.3 million euros as of June…
Abivax: losses deepened in the first half – 09/22/2023 at 1:45 p.m.
(CercleFinance.com) – The biotechnology company Abivax publishes a net loss of 52 million euros for the first half of 2023, compared to a loss of 21.2 million a year earlier,…
Abivax: a change to the board of directors – 09/22/2023 at 2:18 p.m.
(CercleFinance.com) – Alongside the publication of its half-yearly reports, Abivax announces the appointment of Paolo Rampulla as a new member of its board of directors. He will now represent Santé…
Abivax accentuates its losses in the first half
(AOF) – Abivax announces that its cash flow as of June 30, 2023 amounts to 114.4 million euros compared to 27.0 million euros at the end of 2022. The biotech…